

Research article

## Fusion of the *NUP98* gene with the *LEDGF/p52* gene defines a recurrent acute myeloid leukemia translocation

Damian J Hussey<sup>1,2</sup>, Sarah Moore<sup>3</sup>, Mario Nicola<sup>3</sup> and Alexander Dobrovic<sup>\*4</sup>

Address: <sup>1</sup>Department of Haematology-Oncology, The Queen Elizabeth Hospital Woodville, SA 5011, Australia, <sup>2</sup>University of Adelaide Department of Medicine, The Queen Elizabeth Hospital Woodville, SA 5011, Australia, <sup>3</sup>Department of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA 5006, Australia and <sup>4</sup>Molecular Pathology, Department of Pathology, Peter MacCallum Cancer Institute, Locked Bag No 1 A'Beckett Street, Melbourne, Victoria, 8006, Australia

E-mail: Damian J Hussey - damian.hussey@adelaide.edu.au; Sarah Moore - sarah.moore@imvs.sa.gov.au; Mario Nicola - mario.nicola@imvs.sa.gov.au; Alexander Dobrovic\* - a.dobrovic@pmci.unimelb.edu.au

\*Corresponding author

Published: 23 November 2001

Received: 1 October 2001

BMC Genetics 2001, 2:20

Accepted: 23 November 2001

This article is available from: <http://www.biomedcentral.com/1471-2156/2/20>

© 2001 Hussey et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact [info@biomedcentral.com](mailto:info@biomedcentral.com)

### Abstract

**Background:** The *NUP98* gene is involved in multiple rearrangements in haematological malignancy. The leukemic cells in an acute myeloid leukemia (AML) patient with a t(9;11)(p22;p15) were recently shown to have a fusion between the *NUP98* gene and the *LEDGF* gene but it was not demonstrated that this fusion was recurrent in other leukaemia patients with the same translocation.


**Results:** We used RT-PCR to analyse the leukemic cells from an AML patient who presented with a cytogenetically identical translocation as the sole chromosomal abnormality. A *NUP98-LEDGF* fusion transcript was observed and confirmed by sequencing. The reciprocal transcript was also observed. The fusion transcript was not detectable during remission and recurred at relapse. The breakpoints in the *NUP98* and *LEDGF* genes were different to those previously reported. The *NUP98* breakpoint occurs in the intron between exons 8 and 9. It is the most 5' breakpoint reported in a translocation involving the *NUP98* gene. All of the *LEDGF* gene is included in the fusion except for exon 1 which codes for the first 24 amino terminal amino acids.

**Conclusions:** Our results show that fusion of the *NUP98* and *LEDGF* genes is a new recurrent translocation in AML.

### Background

The translocation, t(9;11)(p22;p15), was first reported in a patient with AML M1 [1]. Recently, a second AML M1 patient with a cytogenetically identical translocation was shown to have a fusion transcript between the 5' end of the *NUP98* gene on 11p15 and the 3' end of the *LEDGF* gene on 9p22 [2].

We have identified a third AML patient with a cytogenetically identical translocation. The patient, a 60 year old Caucasian woman presented with a white cell count of  $1.5 \times 10^9/L$  due to neutropenia. The bone marrow showed 50% blasts and 30% promyelocytes. She was diagnosed as AML M2. Cytogenetics showed 46,XX,t(9;11)(p22;p15) [13 cells]/46,XX [2 cells]. Induc-



**Figure 1**  
**RT-PCR analysis of *NUP98-LEDGF* expression.** RT-PCR for the *NUP98-LEDGF* fusion was performed as outlined in the materials and methods. RNA samples are from peripheral blood mononuclear cells taken from a normal donor (lane 1), bone marrow mononuclear cells taken from t(9;11) patient presentation (lane 2), and peripheral blood mononuclear cells taken from t(9;11) patient remission (lane 3) and relapse (lane 4). Lane 5 is a relapse specimen negative control RT-PCR without reverse transcriptase. M is pUC19/HpaII molecular weight marker. The lower panel shows the corresponding *PBGD* PCR control reactions.

tion chemotherapy with ARA-C, idarubicin and etoposide was abandoned after the patient developed a severe neutropenic reaction at the end of the first course. Nevertheless, complete haematological and cytogenetic remission was obtained. After 54 months, the patient relapsed with frank leukemia and a white cell count of  $50 \times 10^9/L$ . Due to the patient's wishes, only supportive therapy was given, and she died of her disease a few days later with a rapidly escalating blast cell burden. Cytogenetics of the relapse peripheral blood showed the same karyotype as at presentation 46,XX,t(9;11)(p22;p15) [19 cells]/46,XX [3 cells].

We analysed the leukemic cells from this patient in order to determine whether the fusion of *NUP98* and *LEDGF* as a result of the t(9;11)(p22;p15) is a recurrent event in AML.

### Results and discussion

The *NUP98* gene is known to be involved in multiple rearrangements in haematological malignancy [3–10]. The 11p15 breakpoint in our patient suggested possible disruption of the *NUP98* gene. We therefore attempted a 3'RACE approach to test for the presence of a fusion mRNA using a method similar to that used to identify *RAP1GDS1* as a fusion partner of *NUP98* [9]. As the most

5' break in *NUP98* known at the time occurred in the intron after exon 10 [9], we used a *NUP98* forward primer from exon 9 for 3'RACE. This approach resulted in a number of RT-PCR products from the t(9;11) patient that were different in size from the *NUP98* 3'RACE products amplified from normal individuals. However sequence analysis of these products showed that they resulted from partially spliced *NUP98* mRNAs rather than novel fusion mRNAs (results not shown).

Subsequently, an AML patient was reported in which the t(9;11)(p22;p15) resulted in an in-frame fusion of the *NUP98* and *LEDGF* genes [2]. This involved fusion of *NUP98* exon 9 to *LEDGF* exon 6. As RACE of our patient had failed to detect any fusions including exon 9 of *NUP98*, we used a *NUP98* primer from exon 8 with a *LEDGF* reverse primer from exon 6 for RT-PCR (Figure 1). An RT-PCR product was obtained in which exon 8 of *NUP98* was fused in-frame to exon 2 of *LEDGF*. The *NUP98* breakpoint thus maps to the 5.5 kb intron between exons 8 and 9 and is the most 5' *NUP98* breakpoint reported to date. The *LEDGF* breakpoint in our patient is more 5' than that found in the patient reported by Ahuja et al [2] and occurs within the 3.5 kb intron between exons 1 and 2.

We also used RT-PCR to assess expression of the *NUP98-LEDGF* fusion mRNA in remission peripheral blood taken twenty months after presentation. Using standard PCR conditions with 35 cycles of PCR (Figure 1), there was no fusion transcript visible. Even after first round PCR with 45 cycles followed by fully nested PCR with 45 cycles we did not detect *NUP98-LEDGF* fusion mRNA in the remission sample (data not shown). However, RT-PCR of the relapse specimen showed that the *NUP98-LEDGF* transcript was re-expressed consistent with the association of the translocation with the disease.

We were able to amplify the reciprocal *LEDGF-NUP98* fusion transcript at presentation and relapse. Sequencing of this product showed an in-frame fusion of exon 2 of *LEDGF* to exon 9 of *NUP98* as expected. The reciprocal transcript is unlikely to be important in the pathogenesis of the disease as the previous report did not observe a reciprocal fusion transcript [2]. However, it is possible that the reciprocal fusion transcript may modulate the course of the disease particularly in the light of the less aggressive form of the disease seen in our patient. Similar patient to patient differences in whether or not the reciprocal transcript is expressed have also been noted for other fusions including *BCR-ABL* and *NUP98-RAP1GDS1* [9,11].

We were also able to obtain RNA using fixed leukemic cells from the first reported t(9;11) patient [1]. This RNA

was highly degraded and had an average length of 200 bases. Despite being able to amplify a 400 bp *NUP98* RT-PCR product, we were unable to amplify a smaller product corresponding to either of the 2 known *NUP98-LEDGF* fusions nor any of a number of other potential *NUP98-LEDGF* fusions that we tried.

The previously reported *NUP98-LEDGF* transcript [2] encodes a protein fusing the amino terminus of the *NUP98* gene containing 28 of the 38 FG repeats with exon 6 onwards of p52/75. FG repeats in *NUP98* fusion proteins have been shown to act as transactivation domains which recruit CBP/p300 [8,12]. The minimum number of FG repeats which are important for the transforming properties of *NUP98* fusion proteins has not yet been defined. The fusion in our patient contains 23 FG repeats from *NUP98*. Interestingly, just after the breakpoint *LEDGF* exon 2 codes for an additional FG residue. It is unknown whether this residue is important for the function of the *NUP98-LEDGF* fusion protein.

The *LEDGF* gene codes for 2 transcriptional co-activators, p75 (*LEDGF*: Lens Epithelium Derived Growth Factor) and p52 which have different 3' ends generated by alternative splicing [15,13]. Both *NUP98-p52* and *NUP98-p75* fusion mRNAs were seen in our patient at presentation and relapse (data not shown) as well as in the previously characterised t(9;11) patient [2]. It remains to be determined whether one transcript is more important in the leukemogenic process.

p52 and p75 both contain a PWWP domain at their amino terminus [14]. PWWP is the core motif of a 70 amino acid domain found in a variety of nuclear proteins [14].

The PWWP domain was lost in the *NUP98-LEDGF* fusion described by Ahuja et al [2] and disrupted in the fusion described here. Interestingly, the PWWP domain is also found in *NSD1*, the most recently identified *NUP98* partner gene and is absent in the *NUP98-NSD1* fusion transcript [10].

The three AML patients with the t(9;11)(p22;p15) vary in their clinical picture (Table 1). At this stage, it is too early to determine which clinicopathological features are a hallmark of this translocation, especially as it is not clear as to whether the first patient's translocation has a similar molecular basis to the other two. Patients 2 and 3 have a more mature myeloid phenotype than that seen in patient 1. All three presented with the t(9;11)(p22;p15) as their sole cytogenetic abnormality. At relapse, the leukemic cells of both patients 2 and 3 had the same karyotype as at presentation whereas the relapse karyotype of patient 1 no longer showed the translocation.

Some *NUP98* translocations are associated with secondary leukemias that occur after treatment with topoisomerase II inhibitors [3–8,15]. The patient in this report had not received chemotherapy prior to her disease and prior chemotherapy was not mentioned in either of the other two case reports [1,2]. It seems that t(9;11)(p22;p15) is preferentially associated with de novo AML rather than therapy related AML.

## Conclusions

Our results show that fusion of the *NUP98* and *LEDGF* genes is a recurrent translocation in AML. Further study is required to determine how this fusion gene promotes leukemia.

**Table 1: Clinical features, immunophenotype of patients with the t(9;11)(p22p15).**

Patient	Sex/Age	WCC × 10 <sup>9</sup> /L	Diagnosis	Survival (months)	Immunophenotype (where less than 50% of cells are involved, the fraction is given).	Reference
1	F/20	63.8	AML M1	3	CD33 (50%), CD13 (10%) negative for CD11b, CD14 HLA DR, CD34 CD19, CD22, negative for CD10 negative for CD2, CD5, CD7, CD41, CD61, CD62 Nuclear TdT negative. Blasts were positive for PAS, Sudan black and myeloperoxidase and negative for non-specific esterase.	1
2	M/52	50.5	AML M1	9	CD33, CD13, CD11c, CD15 (15%), CD36 HLA-DR, negative for CD34 negative for CD10, CD19, CD20, CD56 CD4 (20%), negative for CD5, CD7 Blasts were positive for myeloperoxidase with a subset positive for non-specific esterase.	2
3	F/60	1.5	AML M2	54	CD33, CD13, CD11b (14%) negative for CD34, HLA-DR negative for CD10, CD19, CD20 negative for CD2, CD3, CD5	This report

Details of the three patients discussed in this study are presented. All features except for survival are at presentation. Where surface markers are positive in less than 50% of cells, the proportion of positive cells is indicated in parentheses.

## Materials and methods

### RT-PCR analysis

RNA was obtained from bone marrow or peripheral blood mononuclear cells using Trizol (Invitrogen). RNA was reverse transcribed using Superscript II (Invitrogen). 3' RACE was performed using the 3' RACE System for Rapid Amplification of cDNA Ends (Invitrogen). The manufacturer's protocol for "First Strand cDNA Synthesis of Transcripts with High GC Content" was used. RT-PCR to amplify the *NUP98-LEDGF* fusion was performed using a *NUP98* forward primer from exon 8 (N988F 5'ACCAGCCTCTTCAGCAAACCATTTG3') and a *LEDGF* reverse primer from exon 6 (L826R 5'AACAGATGCTGTTGCTGTTGTCAC3'). *NUP98* exons are numbered according to Genbank ABO40538 and *LEDGF* exons are numbered according to reference 16. Subsequently, the N988F primer was used in combination with either a p52 reverse primer (5'CTTCATCTCTTGTGTTGCTCCACTTG3') or a p75 reverse primer (5'CTCAGCATGTATCCTTTGAAGTCG3') to amplify *NUP98-p52* and *NUP98-p75* fusion transcripts respectively. The *PBGD* transcript was amplified using primers specific for the housekeeping isoform, (5'CTTTCCAAGCGGAGCCATGTCTGG3' and 5'CATGAGGGTTTTCCCGCTTGCAGA3'). PCR was performed using HotStarTaq (Qiagen) according to the manufacturer's instructions with an initial incubation at 95°C for 15 minutes followed by 35 cycles of 96°C for 30 seconds, 65°C for 45 seconds and 72°C for 1 minute.

## Acknowledgements

We thank Professor LC Chan for fixed cells and information on patient 1 and Marilyn Slovak for supplying further information on patient 2. We thank John Norman and Professor RE Sage of the Haematology-Oncology Department of the Queen Elizabeth Hospital for their support and information on patient 3. This work is supported by a National Health & Medical Research Council grant to AD.

## References

1. Ha SY, Chan LC: **Biphenotypic leukemia with t(9;11)(p22;p15).** *Cancer Genet Cytogenet* 1994, **76**:116-117
2. Ahuja HG, Hong J, Aplan PD, Tcheurekdjian L, Forman SJ, Slovak ML: **t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF).** *Cancer Res* 2000, **60**:6227-6229
3. Borrow J, Shearman AM, Stanton VP Jr, et al: **The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 to class I homeoprotein HOXA9.** *Nature Genet* 1996, **12**:159-167
4. Nakamura T, Largaespada DA, Lee MP, et al: **Fusion of the nucleoporin gene NUP98 to HOXA9 by chromosomal translocation t(7;11)(p15;p15) in human myeloid leukemia.** *Nature Genet* 1996, **12**:154-158
5. Arai Y, Hosoda F, Kobayashi H, et al: **The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene NUP98 with the putative RNA helicase gene DDX10.** *Blood* 1997, **89**:3936-3944
6. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD: **NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.** *Cancer Res* 1998, **58**:4269-4273
7. Nakamura T, Yamazaki Y, Hatano Y, Miura I: **NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15).** *Blood* 1999, **94**:741-747

8. Ahuja HG, Felix CA, Aplan PD: **The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOPI fusion.** *Blood* 1999, **94**:3258-3261
9. Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A: **The t(4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia.** *Blood* 1999, **94**:2072-2079
10. Jaju RJ, Fidler C, Haas OA, et al: **A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia.** *Blood* 2001, **98**:1264-1267
11. Melo JV, Gordon DE, Cross NC, Goldman JM: **The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.** *Blood* 1993, **81**:158-165
12. Kasper LH, Brindle PK, Schnabel CA, et al: **CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOX9 oncogenicity.** *Mol Cell Biol* 1999, **19**:764-776
13. Ge H, Si Y, Roeder RG: **Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation.** *EMBO J* 1998, **17**:6723-6729
14. Stec I, Nagl SB, van Ommen GJ, den Dunnen JT: **The PWWP domain: a potential protein-protein interaction domain in nuclear proteins influencing differentiation?** *FEBS Lett* 2000, **473**:1-5
15. Ahuja HG, Felix CA, Aplan PD: **Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations.** *Genes Chromosomes Cancer* 2000, **29**:96-105
16. Singh DP, Kimura A, Chylack LT Jr, Shinohara T: **Lens epithelium-derived growth factor (LEDGF/p75) and p52 are derived from a single gene by alternative splicing.** *Gene* 2000, **242**:265-273

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedCentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)